"Global Parkinsons Disease Therapeutics Market Overview:
Global Parkinsons Disease Therapeutics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Parkinsons Disease Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Parkinsons Disease Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Parkinsons Disease Therapeutics Market:
The Parkinsons Disease Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Parkinsons Disease Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Parkinsons Disease Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Parkinsons Disease Therapeutics market has been segmented into:
Levodopa
Dopamine agonists
MAO-B inhibitors
Anticholinergics
Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
among Others
By Application, Parkinsons Disease Therapeutics market has been segmented into:
Oral
Injectable
Nasal
Transdermal
Others (Rectal
Sublingual
among Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Parkinsons Disease Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Parkinsons Disease Therapeutics market.
Top Key Players Covered in Parkinsons Disease Therapeutics market are:
Teva Pharmaceutical Industries Ltd.
Novartis AG
GlaxoSmithKline Plc.
AbbVie Inc.
Merck & Co.
Inc.
Zydus Cadila
Dr. Reddy’s Laboratories
Sun Pharmaceutical Industries Ltd.
Cipla Inc.
Boehringer Ingelheim International GmbH
Denali Therapeutics Inc.
Biogen Inc.
Prevail Therapeutics
Eli Lilly and Company and Voyager Therapeutics.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Parkinsons Disease Therapeutics Market by Type
4.1 Parkinsons Disease Therapeutics Market Snapshot and Growth Engine
4.2 Parkinsons Disease Therapeutics Market Overview
4.3 Levodopa
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Levodopa: Geographic Segmentation Analysis
4.4 Dopamine agonists
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Dopamine agonists: Geographic Segmentation Analysis
4.5 MAO-B inhibitors
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 MAO-B inhibitors: Geographic Segmentation Analysis
4.6 Anticholinergics
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Anticholinergics: Geographic Segmentation Analysis
4.7 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine: Geographic Segmentation Analysis
4.8 among Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 among Others: Geographic Segmentation Analysis
Chapter 5: Parkinsons Disease Therapeutics Market by Application
5.1 Parkinsons Disease Therapeutics Market Snapshot and Growth Engine
5.2 Parkinsons Disease Therapeutics Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation Analysis
5.4 Injectable
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Injectable: Geographic Segmentation Analysis
5.5 Nasal
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Nasal: Geographic Segmentation Analysis
5.6 Transdermal
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Transdermal: Geographic Segmentation Analysis
5.7 Others (Rectal
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others (Rectal: Geographic Segmentation Analysis
5.8 Sublingual
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Sublingual: Geographic Segmentation Analysis
5.9 among Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 among Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Parkinsons Disease Therapeutics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 NOVARTIS AG
6.4 GLAXOSMITHKLINE PLC.
6.5 ABBVIE INC.
6.6 MERCK & CO.
6.7 INC.
6.8 ZYDUS CADILA
6.9 DR. REDDY’S LABORATORIES
6.10 SUN PHARMACEUTICAL INDUSTRIES LTD.
6.11 CIPLA INC.
6.12 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.13 DENALI THERAPEUTICS INC.
6.14 BIOGEN INC.
6.15 PREVAIL THERAPEUTICS
6.16 ELI LILLY AND COMPANY AND VOYAGER THERAPEUTICS.
Chapter 7: Global Parkinsons Disease Therapeutics Market By Region
7.1 Overview
7.2. North America Parkinsons Disease Therapeutics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Levodopa
7.2.4.2 Dopamine agonists
7.2.4.3 MAO-B inhibitors
7.2.4.4 Anticholinergics
7.2.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.2.4.6 among Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oral
7.2.5.2 Injectable
7.2.5.3 Nasal
7.2.5.4 Transdermal
7.2.5.5 Others (Rectal
7.2.5.6 Sublingual
7.2.5.7 among Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Parkinsons Disease Therapeutics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Levodopa
7.3.4.2 Dopamine agonists
7.3.4.3 MAO-B inhibitors
7.3.4.4 Anticholinergics
7.3.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.3.4.6 among Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oral
7.3.5.2 Injectable
7.3.5.3 Nasal
7.3.5.4 Transdermal
7.3.5.5 Others (Rectal
7.3.5.6 Sublingual
7.3.5.7 among Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Parkinsons Disease Therapeutics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Levodopa
7.4.4.2 Dopamine agonists
7.4.4.3 MAO-B inhibitors
7.4.4.4 Anticholinergics
7.4.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.4.4.6 among Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oral
7.4.5.2 Injectable
7.4.5.3 Nasal
7.4.5.4 Transdermal
7.4.5.5 Others (Rectal
7.4.5.6 Sublingual
7.4.5.7 among Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Parkinsons Disease Therapeutics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Levodopa
7.5.4.2 Dopamine agonists
7.5.4.3 MAO-B inhibitors
7.5.4.4 Anticholinergics
7.5.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.5.4.6 among Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oral
7.5.5.2 Injectable
7.5.5.3 Nasal
7.5.5.4 Transdermal
7.5.5.5 Others (Rectal
7.5.5.6 Sublingual
7.5.5.7 among Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Parkinsons Disease Therapeutics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Levodopa
7.6.4.2 Dopamine agonists
7.6.4.3 MAO-B inhibitors
7.6.4.4 Anticholinergics
7.6.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.6.4.6 among Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oral
7.6.5.2 Injectable
7.6.5.3 Nasal
7.6.5.4 Transdermal
7.6.5.5 Others (Rectal
7.6.5.6 Sublingual
7.6.5.7 among Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Parkinsons Disease Therapeutics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Levodopa
7.7.4.2 Dopamine agonists
7.7.4.3 MAO-B inhibitors
7.7.4.4 Anticholinergics
7.7.4.5 Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
7.7.4.6 among Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oral
7.7.5.2 Injectable
7.7.5.3 Nasal
7.7.5.4 Transdermal
7.7.5.5 Others (Rectal
7.7.5.6 Sublingual
7.7.5.7 among Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Parkinsons Disease Therapeutics Scope:
|
Report Data
|
Parkinsons Disease Therapeutics Market
|
|
Parkinsons Disease Therapeutics Market Size in 2025
|
USD XX million
|
|
Parkinsons Disease Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Parkinsons Disease Therapeutics Base Year
|
2024
|
|
Parkinsons Disease Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics, Eli Lilly and Company and Voyager Therapeutics..
|
|
Key Segments
|
By Type
Levodopa
Dopamine agonists
MAO-B inhibitors
Anticholinergics
Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine
among Others
By Applications
Oral
Injectable
Nasal
Transdermal
Others (Rectal
Sublingual
among Others
|
